Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer

Phase 2

Not yet recruiting

• Conditions: Pancreatic Cancer
• Interventions: Drug: Nimotuzumab; Drug: GX; Drug: Placebo

• Registration Number: NCT06409429
• Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Brief Summary

This is a prospective, multicenter, randomized, double-blind, placebo-controlled study. The main purpose of the study is to evaluate the clinical efficacy and safety of Nimotuzumab combined with GX for postoperative adjuvant treatment of pancreatic cancer.

Detailed Description

This clinical study is designed as a prospective, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy and safety of Nimotuzumab combined with GX (gemcitabine plus capecitabine) compared with GX only for resected pancreatic cancer. About 146 patients will be enrolled in this study and randomly divided into experim...

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Status Verified: 2024-05
• Study Start: 2024-05-01
• Study First Submitted: 2024-05-07
• Study First Submitted QC: 2024-05-07
• Last Update Submitted: 2024-05-07
• Study First Posted: 2024-05-10
• Last Update Posted: 2024-05-10
• Primary Completion: 2027-05-30
• Study Completion: 2027-05-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 146

Inclusion Criteria

• 1. Able and willing to provide a written informed consent.
• 2. Age 18-75 years old, gender unlimited;
• 3. Histologically or cytologically confirmed resected pancreatic ductal adenocarcinoma (PDAC), resectable evaluation is based on criteria of NCCN guidelines, no evidence of distant metastasis as demonstrated by imaging;
• 4. Postoperative pathology suggested R0/R1 resection;
• 5. Adequate organ and bone marrow function, defined as follows: absolute neutrophil count (ANC)≥1.5×10^9/L; platelets≥100×10^9/L; hemoglobin≥9.0 g/dL; serum total bilirubin (TBIL)≤1.5×ULN; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times the upper limit of normal (ULN); serum creatinine≤1.5×ULN or estimated creatinine clearance > 60 mL/min;
• 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
• 7. Postoperative survival is expected to be ≥3 months;
• 8. Fertile subjects are willing to take contraceptive measures during the study period.

Read More

Exclusion Criteria

• 1. Prior neo-adjuvant treatment, radiation therapy, or systemic therapy for pancreatic adenocarcinoma;
• 2. Accompanied by other serious diseases, including but not limited to: active infections; unmanageable diabetes mellitus and uncontrolled hypertension (SBP>160mmHg or DBP>100mmHg); compensatory heart failure (NYHA grade III and IV), unstable angina or poorly controlled arrhythmias within 3 months prior to randomization; presence of uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage; severe portal hypertension; gastric outlet obstruction; Respiratory insufficiency and Severe lung disease; Central Nervous System Disease or mental illness;
• 3. History of other malignancies (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);
• 4. bleeding or clotting disorder;
• 5.Postoperative complications such as bleeding, pancreatic fistula, gastric obstruction, abdominal infection, and biliary fistula, which made the patient unable to receive adjuvant therapy within 12 weeks after surgery;
• 6. Known allergy to prescription or any component of the prescription used in this study;
• 7. Factors that significantly affect oral drug absorption, such as dysphagia, chronic diarrhea, gastrointestinal obstruction, etc;
• 8. Known HIV, or syphilis infection, or active hepatitis (hepatitis B, hepatitis C);
• 9.Other reasons that are not suitable to participate in this study according to the researcher's judgment

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Experimental group (Nimotuzumab+ GX)	Nimotuzumab	-
Experimental group (Nimotuzumab+ GX)	GX	-
Control group (Placebo+ GX)	GX	-
Control group (Placebo+ GX)	Placebo	-

Primary Outcome Measures

Name	Time	Method
relapse-free survival (RFS)	Up to 24 months	The time from the date of surgery to the disease recurrence or death, whichever is earlier.

Secondary Outcome Measures

Name	Time	Method
distant metastasis-free survival (DMFS)	Up to 24 months	The time from the date of surgery to the first distant metastasis or death due to any cause, whichever is earlier.
overall survival (OS)	Up to 24 months	The time from the date of surgery to death due to any cause.
tumor-related markers	Up to 24 months	To explore the influence of tumor-related markers (such as KRAS, EGFR) on prognosis.
adverse events	Up to 30 days after last administration.	Frequency and severity of adverse events

Trial Locations

Locations (1)

Tianjin Medical University Cancer Institute and Hospital; 🇨🇳 Tianjin, China